50 and older, any sex, with Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percentage of Participants With Stable Vision at Week 52Primary· Baseline to Week 52
Stable vision was defined as vision loss of fewer than 15 letters in Best-corrected Visual Acuity (BCVA) from baseline. BCVA is measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The percentage of participants with a BCVA loss of fewer than 15 letters are reported. Study eye was defined as the eye that m
Group
Value
95% CI
Abicipar Pegol 2 mg (2Q8)
94.8
Abicipar Pegol 2 mg (2Q12)
91.3
Ranibizumab (rQ4)
96.0
Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) in the Study Eye at Week 52Secondary· Baseline to Week 52
BCVA was measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Mixed-effect model for repeated measures (MMRM) analysis was used. Study eye is defined as the eye that meets the entry criteria. If both the eyes met all of the entry criteria, the eye with worse BCVA at baseline (Day 1) was selected. If BCVA v
Group
Value
95% CI
Abicipar Pegol 2 mg (2Q8)
8.3
± 14.3
Abicipar Pegol 2 mg (2Q12)
7.3
± 13.8
Ranibizumab (rQ4)
8.3
± 11.8
Mean Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye at Week 52Secondary· Baseline to Week 52
CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system that provides high-resolution imaging sections of the retina. SD-OCT is performed in the study eye after pupil dilation. A negative change from Baseline indicates improvement and a positive change from baseline indicates worsening. Study eye is defined as the eye that meets the entry criteria. If both the eyes met all of the entry criteria, the eye with worse BCVA at baseline (Day 1) was selected. If BCVA values for both eyes were identical then participant had to select the non-domin
Group
Value
95% CI
Abicipar Pegol 2 mg (2Q8)
-146.8
± 118.1
Abicipar Pegol 2 mg (2Q12)
-141.7
± 127.1
Ranibizumab (rQ4)
-147.1
± 126.2
Percentage of Participants With BCVA Gain of More Than 15 Letters From Baseline in the Study Eye at Week 52Secondary· Baseline to Week 52
BCVA is measured using an eye chart and is reported as the number of letters read correctly using the Early Treatment of Diabetic Retinopathy Study (ETDRS) Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The percentage of participants with a BCVA gain of more than 15 letters are noted. Study eye is defined as the eye that meets the entry criteria. If both the eyes met all of the entry criteria, the
Group
Value
95% CI
Abicipar Pegol 2 mg (2Q8)
28.2
Abicipar Pegol 2 mg (2Q12)
24.4
Ranibizumab (rQ4)
26.7
Mean Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) Composite Score at Week 52Secondary· Baseline to Week 52
NEI-VFQ-25 consists of 25 vision-targeted questions that represent 11 vision-related quality of life subscales and one general health item. Responses of individual participants were recorded as scores that ranged between 0 (worst) to 100 (best vision related function) with higher scale indicating better vision. Overall composite score is then calculated by averaging over all 11 vision-targeted subscale scores, excluding general health score. Overall composite score was calculated based on mean of non-missing subscales. Study eye: eye that meets entry criteria. If both eyes met all of entry cri
Group
Value
95% CI
Abicipar Pegol 2 mg (2Q8)
2.8
± 0.7
Abicipar Pegol 2 mg (2Q12)
2.4
± 0.7
Ranibizumab (rQ4)
4.4
± 0.7
Adverse events — posted to ClinicalTrials.gov
Time frame: From the first dose up to last dose (Up to Week 104).
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Abicipar Pegol 2 mg (2Q8)
Serious: 94/313 (30%)
Deaths: 11/313
Abicipar Pegol 2 mg (2Q12)
Serious: 83/314 (26%)
Deaths: 6/314
Ranibizumab (rQ4)
Serious: 78/315 (25%)
Deaths: 7/315
Serious adverse events (249 terms)
Reaction
System
Abicipar Pegol 2 mg (2Q8)
Abicipar Pegol 2 mg (2Q12)
Ranibizumab (rQ4)
Pneumonia
Infections and infestations
—
—
—
Uveitis
Eye disorders
—
—
—
Basal cell carcinoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NCT02462928 — A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
· Phase 3
· completed
Other recruiting trials for Macular Degeneration
Currently open trials in the same condition.
NCT07440225 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
· Phase 2, PHASE3
· recruiting
NCT07085533 — Natural History Study of Inherited Retinal Diseases
· recruiting
NCT06805474 — A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
· recruiting
NCT06779773 — A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
· recruiting
NCT06635148 — A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Se
· Phase 2
· recruiting
Other Allergan trials
Trials by the same sponsor.
NCT04609020 — Study to Evaluate Subject Satisfaction With Facial Appearance and Impact of Combined Facial Treatment
· Phase 4
· completed
NCT05452070 — A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft
· Phase 3
· completed
NCT05393089 — Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopi
· Phase 2
· withdrawn
NCT05152576 — A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants Wi
· Phase 2
· completed
NCT05088980 — Study to Assess Effectiveness and Adverse Events of JUVEDERM VOLBELLA With Lidocaine Injection in Correcting Infraorbita
· Phase 3
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Allergan
Last refreshed: 30 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02462486.